Genetic determinants of chronic oxaliplatin-induced peripheral neurotoxicity: A genome-wide study replication and meta-analysis

Journal of the Peripheral Nervous System

Volumn 20, Issue 1, 2015, Pages 15-23

  Terrazzino, Salvatore ^a   Argyriou, Andreas A ^b,c   Cargnin, Sarah ^a   Antonacopoulou, Anna G ^c   Briani, Chiara ^d   Bruna, Jordi ^e   Velasco, Roser ^e   Alberti, Paola ^f   Campagnolo, Marta ^d   Lonardi, Sara ^g   Cortinovis, Diego ^h   Cazzaniga, Marina ^h   Santos, Cristina ^e   Kalofonos, Haralabos P ^c   Canonico, Pier Luigi ^a   Genazzani, Armando A ^a   Cavaletti, Guido ^f  

^a UNIVERSITY OF EASTERN PIEDMONT   (Italy)

^b UNIVERSITY GENERAL HOSPITAL OF PATRAS   (Greece)

^c UNIVERSITY HOSPITAL OF PATRAS   (Greece)

^d UNIVERSITY OF PADOVA   (Italy)

^e HOSPITAL UNIVERSITARI DE BELLVITGE   (Spain)

^f UNIVERSITY OF MILANO BICOCCA   (Italy)

^g VENETO INSTITUTE OF ONCOLOGY IOV IRCCS   (Italy)

^h SAN GERARDO HOSPITAL   (Italy)

Author keywords

chemotherapy induced peripheral neuropathy; meta analysis; neurotoxicity; oxaliplatin; polymorphisms

Indexed keywords

OXALIPLATIN; TRANSCRIPTION FACTOR FOXC1; ACID ANHYDRIDE HYDROLASE; ACYLPHOSPHATASE; ANTINEOPLASTIC AGENT; PLATINUM COMPLEX;

ACYP2 GENE; ADULT; ARTICLE; BTG4 GENE; CAMK2N1 GENE; CHRONIC DISEASE; COHORT ANALYSIS; COLORECTAL CANCER; CONTROLLED STUDY; DATA ANALYSIS; DISEASE ASSOCIATION; DISEASE MARKER; DISEASE SEVERITY; DLEU7 GENE; FARS2 GENE; FEMALE; FOXC1 GENE; GENE; GENE FREQUENCY; GENE FUNCTION; GENE IDENTIFICATION; GENETIC ASSOCIATION; GENETIC VARIABILITY; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; NEUROTOXICITY; OUTCOME ASSESSMENT; PERIPHERAL NEUROTOXICITY; PRIORITY JOURNAL; SCORING SYSTEM; SINGLE NUCLEOTIDE POLYMORPHISM; SYNDROME DELINEATION; TAC1 GENE; AGED; CHEMICALLY INDUCED; COLORECTAL NEOPLASMS; GENETICS; GENOME-WIDE ASSOCIATION STUDY; META ANALYSIS; PERIPHERAL NEUROPATHY; VERY ELDERLY;

ACID ANHYDRIDE HYDROLASES; ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; COLORECTAL NEOPLASMS; FEMALE; GENOME-WIDE ASSOCIATION STUDY; GENOTYPE; HUMANS; MALE; MIDDLE AGED; ORGANOPLATINUM COMPOUNDS; PERIPHERAL NERVOUS SYSTEM DISEASES; POLYMORPHISM, SINGLE NUCLEOTIDE;

EID: 84930973584     PISSN: 10859489     EISSN: 15298027     Source Type: Journal    
DOI: 10.1111/jns.12110     Document Type: Article

References (26)

1. Argyriou AA, Polychronopoulos P, Iconomou G, Chroni E, Kalofonos HP, (2008). A review on oxaliplatin-induced peripheral nerve damage. Cancer Treat Rev 34: 368-377.
2. Argyriou AA, Cavaletti G, Briani C, Velasco R, Bruna J, Campagnolo M, Alberti P, Bergamo F, Cortinovis D, Cazzaniga M, Santos C, Papadimitriou K, Kalofonos HP, (2013a). Clinical pattern and associations of oxaliplatin acute neurotoxicity: a prospective study in 170 patients with colorectal cancer. Cancer 119: 438-444.
3. Argyriou AA, Cavaletti G, Antonacopoulou A, Genazzani AA, Briani C, Bruna J, Terrazzino S, Velasco R, Alberti P, Campagnolo M, Lonardi S, Cortinovis D, Cazzaniga M, Santos C, Psaromyalou A, Angelopoulou A, Kalofonos HP, (2013b). Voltage-gated sodium channel polymorphisms play a pivotal role in the development of oxaliplatin-induced peripheral neurotoxicity: results from a prospective multicenter study. Cancer 119: 3570-3577.
4. Argyriou AA, Kyritsis AP, Makatsoris T, Kalofonos HP, (2014). Chemotherapy-induced peripheral neuropathy in adults: a comprehensive update of the literature. Cancer Manag Res 6: 135-147.
5. Cavaletti G, Frigeni B, Lanzani F, Mattavelli L, Susani E, Alberti P, Cortinovis D, Bidoli P, (2010). Chemotherapy-induced peripheral neurotoxicity assessment: a critical revision of the currently available tools. Eur J Cancer 46: 479-494.
6. Cavaletti G, Alberti P, Marmiroli P, (2011). Chemotherapy-induced peripheral neurotoxicity in the era of pharmacogenomics. Lancet Oncol 12: 1151-1161.
7. Cavaletti G, Cornblath DR, Merkies IS, Postma TJ, Rossi E, Frigeni B, Alberti P, Bruna J, Velasco R, Argyriou AA, Kalofonos HP, Psimaras D, Ricard D, Pace A, Galiè E, Briani C, Dalla Torre C, Faber CG, Lalisang RI, Boogerd W, Brandsma D, Koeppen S, Hense J, Storey D, Kerrigan S, Schenone A, Fabbri S, Valsecchi MG, CI-PeriNomS Group (2013). The chemotherapy- induced peripheral neuropathy outcome measures standardization study: from consensus to the first validity and reliability findings. Ann Oncol 24: 454-462.
8. Cecchin E, D'Andrea M, Lonardi S, Zanusso C, Pella N, Errante D, De Mattia E, Polesel J, Innocenti F, Toffoli G, (2013). A prospective validation pharmacogenomic study in the adjuvant setting of colorectal cancer patients treated with the 5-fluorouracil/leucovorin/oxaliplatin (FOLFOX4) regimen. Pharmacogenomics J 13: 403-409.
9. Custodio A, Moreno-Rubio J, Aparicio J, Gallego-Plazas J, Yaya R, Maurel J, Higuera O, Burgos E, Ramos D, Calatrava A, Andrada E, Lõpez R, Moreno V, Madero R, Cejas P, Feliu J, (2014). Pharmacogenetic predictors of severe peripheral neuropathy in colon cancer patients treated with oxaliplatin-based adjuvant chemotherapy: a GEMCAD group study. Ann Oncol 25: 398- 403.
10. DerSimonian R, Laird N, (1986). Meta-analysis in clinical trials. Control Clin Trials 7: 177-188.
11. Grothey A, Goldberg RM, (2004). A review of oxaliplatin and its clinical use in colorectal cancer. Expert Opin Pharmacother 5: 2159-2170.
12. Kraft P, (2008). Curses-winner's and otherwise-in genetic epidemiology. Epidemiology 19: 649-651.
13. Lau J, Ioannidis JP, Schmid CH, (1997). Quantitative synthesis in systematic reviews. Ann Intern Med 127: 820-826.
14. Lohmueller KE, Pearce CL, Pike M, Lander ES, Hirschhorn JN, (2003). Meta-analysis of genetic association studies supports a contribution of common variants to susceptibility to common disease. Nat Genet 33: 177-182.
15. Motsinger-Reif AA, Jorgenson E, Relling MV, Kroetz DL, Weinshilboum R, Cox NJ, Roden DM, (2013). Genome-wide association studies in pharmacogenomics: successes and lessons. Pharmacogenet Genomics 23: 383-394.
16. Oguri T, Mitsuma A, Inada-Inoue M, Morita S, Shibata T, Shimokata T, Sugishita M, Nakayama G, Uehara K, Hasegawa Y, Ando Y, (2013). Genetic polymorphisms associated with oxaliplatin-induced peripheral neurotoxicity in Japanese patients with colorectal cancer. Int J Clin Pharmacol Ther 51: 475-481.
17. Patel JN, McLeod HL, Innocenti F, (2013). Implications of genome-wide association studies in cancer therapeutics. Br J Clin Pharmacol 76: 370-380.
18. Peng Z, Wang Q, Gao J, Ji Z, Yuan J, Tian Y, Shen L, (2013). Association between GSTP1 Ile105Val polymorphism and oxaliplatin-induced neuropathy: a systematic review and meta- analysis. Cancer Chemother Pharmacol 72: 305-314.
19. Schmoll HJ, Van Cutsem E, Stein A, Valentini V, Glimelius B, Haustermans K, Nordlinger B, van de Velde CJ, Balmana J, Regula J, Nagtegaal ID, Beets-Tan RG, Arnold D, Ciardiello F, Hoff P, Kerr D, Köhne CH, Labianca R, Price T, Scheithauer W, Sobrero A, Tabernero J, Aderka D, Barroso S, Bodoky G, Douillard JY, El Ghazaly H, Gallardo J, Garin A, Glynne-Jones R, Jordan K, Meshcheryakov A, Papamichail D, Pfeiffer P, Souglakos I, Turhal S, Cervantes A, (2012). ESMO Consensus Guidelines for management of patients with colon and rectal cancer. a personalized approach to clinical decision making. Ann Oncol 23: 2479-2516.
20. Sereno M, Gutiérrez-Gutiérrez G, Gõmez-Raposo C, Lõpez- Gõmez M, Merino-Salvador M, Tébar FZ, Rodriguez-Antona C, Casado E, (2014). Oxaliplatin induced-neuropathy in digestive tumors. Crit Rev Oncol Hematol 89: 166-178.
21. Solé X, Guinõ E, Valls J, Iniesta R, Moreno V, (2006). SNPStats: a web tool for the analysis of association studies. Bioinformatics 22: 1928-1929.
22. Stein A, Arnold D, (2012). Oxaliplatin: a review of approved uses. Expert Opin Pharmacother 13: 125-137.
23. Tenesa A, Dunlop MG, (2009). New insights into the aetiology of colorectal cancer from genome-wide association studies. Nat Rev Genet 10: 353-358.
24. Uwah AN, Ackler J, Leighton JC Jr, Pomerantz S, Tester W, (2012). The effect of diabetes on oxaliplatin-induced peripheral neuropathy. Clin Colorectal Cancer 11: 275-279.
25. Véron A, Blein S, Cox DG, (2014). Genome-wide association studies and the clinic: a focus on breast cancer. Biomark Med 8: 287-296.
26. Won HH, Lee J, Park JO, Park YS, Lim HY, Kang WK, Kim JW, Lee SY, Park SH, (2012). Polymorphic markers associated with severe oxaliplatin-induced, chronic peripheral neuropathy in colon cancer patients. Cancer 118: 2828-2836.